Go Pro
→ How Long Does $2.5M Last in Retirement? (From SmartAsset) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Competitors

SAB Biotherapeutics logo
$0.03 +0.00 (+11.91%)
Closing price 09/3/2026 12:01 PM Eastern
Extended Trading
$0.02 0.00 (-4.94%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SABSW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Alvotech?

SAB Biotherapeutics (NASDAQ:SABSW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, Alvotech had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for SAB Biotherapeutics. Alvotech's average media sentiment score of 0.92 beat SAB Biotherapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Alvotech Positive

Summary

Alvotech beats SAB Biotherapeutics on 3 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Apollomics?

SAB Biotherapeutics (NASDAQ:SABSW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Apollomics N/A N/A N/A

In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Apollomics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats SAB Biotherapeutics on 1 of the 1 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Aravive?

SAB Biotherapeutics (NASDAQ:SABSW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Aravive Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aravive beats SAB Biotherapeutics on 2 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

In the previous week, bioAffinity Technologies had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.66 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Negative
SAB Biotherapeutics Neutral

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Summary

bioAffinity Technologies beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

In the previous week, BioVie had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for BioVie and 0 mentions for SAB Biotherapeutics. BioVie's average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score.

Company Overall Sentiment
BioVie Neutral
SAB Biotherapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

BioVie beats SAB Biotherapeutics on 1 of the 1 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABSW vs. The Competition

Export
MetricSAB BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.03B$7.26B$12.73B
Dividend YieldN/A3.60%2.53%8.56%
P/E RatioN/A12.66273.3025.25
Price / SalesN/A1,333.94621.3198.12
Price / CashN/A106.8777.8252.26
Price / BookN/A16.3012.896.14
Net IncomeN/A-$22.72M$3.47B$349.01M
7 Day PerformanceN/A0.15%0.52%-0.31%
1 Month PerformanceN/A8.29%5.63%0.64%
1 Year PerformanceN/A52.60%25.30%14.83%

SAB Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABSW
SAB Biotherapeutics
N/A$0.03
+11.9%		N/A-0.8%$0.00N/AN/A140
ALVOW
Alvotech
N/A$0.38
flat		N/A-73.0%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
flat		N/A+42.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.32
+96.9%		N/A+1,001.7%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SABSW) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel